Cancel
Eledon Pharmaceuticals
See Linkedin
Eledon Pharmaceuticals Employees
10 people indexed:
-
xq7vxz@fv00p7.128 Sign up to see email
-
7452@7y2iw6.y8f Sign up to see email
-
David-Alexandre C. Gros
Chief Executive Officer
-
iw7r04w1@sj933s.px1 Sign up to see email
-
f6sq0@bbjf44.i20 Sign up to see email
-
q0v7y6wxwi@wx6q6p.5fx Sign up to see email
-
Keith A. Katkin
Chairman of the Board of Directors
-
Marina Escudero
Vice President, and Head of Clinical Operations
5qga54ji0@h63i1q.9fb Sign up to see emailgk36pqg36@pzi5g6.4tt Sign up to see email -
8gvh9q8@s930jw.sgw Sign up to see email
-
938jzva@8kxkk7.9t9 Sign up to see email
Eledon Pharmaceuticals Company Information
Eledon Pharmaceuticals is a biotechnology company that develops immune-modulating therapies for the management and treatment of life-threatening conditions. The company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand. Eledon conducts both preclinical and clinical studies, focusing on areas such as kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Headquartered in Irvine, California, Eledon has initiated a randomized Phase 2 trial comparing tegoprubart versus standard of care for the prevention of rejection in kidney transplant recipients. Additionally, the company is conducting an ongoing single-arm Phase 1b clinical trial of tegoprubart for the same purpose. Eledon is also evaluating tegoprubart’s potential in other types of organ transplantation, including liver transplantation and xenotransplantation. The company’s mission, ‘One Transplant for Life’, aims to improve both the longevity of the organ and the overall health and quality of life for transplant recipients.
Report inaccurate information
Report inaccurate information
